AngioDynamics (ANGO) to Release Quarterly Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) is projected to issue its Q3 2026 results before the market opens on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $76.7670 million for the quarter. Individuals may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Thursday, April 2, 2026 at 8:00 AM ET.

AngioDynamics Stock Up 5.6%

AngioDynamics stock opened at $11.22 on Thursday. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $13.99. The company has a market capitalization of $462.49 million, a P/E ratio of -16.75 and a beta of 0.48. The stock’s 50 day moving average is $10.79 and its 200 day moving average is $11.54.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently bought and sold shares of the business. Millennium Management LLC boosted its holdings in shares of AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after acquiring an additional 393,682 shares during the last quarter. Kotler Kevin purchased a new position in shares of AngioDynamics during the fourth quarter valued at approximately $21,997,000. Armistice Capital LLC lifted its position in AngioDynamics by 7.1% during the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the medical instruments supplier’s stock valued at $18,274,000 after purchasing an additional 108,185 shares during the period. Nuveen LLC lifted its position in AngioDynamics by 40.5% during the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after purchasing an additional 373,110 shares during the period. Finally, State Street Corp boosted its holdings in AngioDynamics by 33.0% in the fourth quarter. State Street Corp now owns 1,272,735 shares of the medical instruments supplier’s stock worth $16,342,000 after purchasing an additional 315,844 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ANGO shares. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, AngioDynamics presently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.